Pentixapharm Holding AG
1.75
EUR
-0.05
(-2.79%)
ISIN
DE000A40AEG0
Return %
Stock
S&P 500
1Y
6.96
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Dirk Pleimes
- Full Time Employees
- 54
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Berlin Germany
- IPO Date
- Oct 3, 2024
- Website
- pentixapharm.com
- Similar Companies
- Business
- Pentixapharm Holding AG is a Germany-based, clinical-stage biopharmaceutical company engaged in the development of targeted radiopharmaceuticals and theranostic solutions for precision oncology, endocrinology, and cardiovascular diseases. The company operates within the biotechnology and pharmaceuticals industry, focusing on molecular imaging and endoradiotherapy based on the chemokine receptor CXCR4 pathway. The company's product and service pipeline comprises: PentixaFor (68Ga-PentixaFor), a first-in-class Gallium-68-labeled diagnostic peptide designed for positron emission tomography (PET/CT) imaging of CXCR4-expressing tissues, advanced in Phase 3 clinical evaluation (including the PANDA trial) for the subtype diagnosis of primary aldosteronism in hypertension, as well as clinical assessments for hematologic malignancies and solid tumors; PentixaTher (90Y-PentixaTher / 177Lu-PentixaTher), a therapeutic radiolabeled peptide designed to deliver localized beta- or auger-emitting radiation to CXCR4-overexpressing malignant cells, under clinical development for hematologic cancers including non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, and central nervous system lymphomas; CXCR4-targeted theranostic platform solutions combining companion diagnostic PET imaging agents with therapeutic radioligands to select eligible patients and monitor treatment responses; and next-generation targeted radionuclide conjugates, including preclinical antibody-radionuclide candidates and immune-escape targeted programs such as CD24-directed therapies for solid tumor oncology. Founded in 2019, Pentixapharm Holding AG is headquartered in Berlin, Germany, and maintains research and operational offices in Würzburg, Germany. The company conducts clinical trials and research collaborations across Europe and internationally, targeting healthcare providers, specialized oncology clinics, and nuclear medicine centers. In October 2024, Pentixapharm completed a corporate spin-off from its former parent company, Eckert & Ziegler SE, and listed its shares on the Prime Standard segment of the Frankfurt Stock Exchange under the ticker symbol PTP. Prior to the public listing in July 2024, the company expanded its early-stage research portfolio by acquiring the target discovery business and laboratory assets of Berlin-based Glycotope GmbH. In January 2025, Pentixapharm sold selected intangible assets acquired from Glycotope to Asian pharmaceutical entities for 6.77 million euros to fulfill related earn-out obligations. Following a strategic operational review in 2025, the company reorganized its clinical development priorities to focus financial and operational resources on its late-stage CXCR4 programs, including the Phase 3 PentixaFor development and PentixaTher clinical basket trials, while optimizing overhead and extending its operational cash runway.